The purpose of this data collection is to determine long term survival rate of ArComXL® highly cross-linked...
Date First Received: June 13, 2008
Last Updated: July 21, 2008
Verified by: Biomet, Inc., July 2008
Clinical Trial Phase: N/A | Start Date: January 2006
Overall Status: Active, not recruiting
Estimated Enrollment: 149
Brief Summary
Official Title: “A Prospective, Non-Controlled, Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement”
Condition Keyword(s):
The purpose of this data collection is to determine long term survival rate of ArComXL® highly cross-linked polyethylene
Study Type: Observational
Study Design: Cohort, Prospective
Study Primary Completion Date: April 2018
Arms, Groups and Cohorts in this Clinical Trial
- : ArComXL® polyethylene
- ArComXL® polyethylene
Outcome Measures for this Clinical Trial
Primary Measures
- Incidence of revisions and removals assessed by the use of a yearly survey mail to patient
- Time Frame: 6 weeks, 1 year, 2 years, 3 years, 5 years, 10 years
Safety Issue?: Yes
- Time Frame: 6 weeks, 1 year, 2 years, 3 years, 5 years, 10 years
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Non inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid Arthritis
- Correction of Functional Deformity
- Treatment of non-union, femoral neck fractures, trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
- Revision of previously failed total hip arthroplasty
- Uncemented applications
Exclusion Criteria:
- Absolute contraindications
- Infection, sepsis and osteomyelitis
- Relative contraindications
- Uncooperative patient or patient with neurologic disorders who are incapable of following directions
- Osteoporosis
- Metabolic disorders which may impair bone formation
- Osteomalacia
- Distant foci of infections which may be spread to the implant site
- Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
- Vascular insufficiency, muscular atrophy or neuromuscular disease
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: N/A
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Biomet Orthopedics, LLC
Overall Clinical Trial Officials and Contacts
Kenneth J Beres, MD Study Director Clinical Research, Biomet Orthopedics, Inc.
Additional Information
Information obtained from ClinicalTrials.gov on August 28, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00698152
Study ID Number: Biomet 12380-326
ClinicalTrials.gov Identifier: NCT00698152
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.